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Abstract
IMPORTANCE People with criminal histories experience high rates of opioid dependence and are
frequent users of acute health care services. It is unclear whether methadone adherence prevents
hospitalizations.
OBJECTIVE To compare hospital admissions during medicated and nonmedicated
methadone periods.
DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study involving linked population-
level administrative data among individuals in British Columbia, Canada, with provincial justice
contacts (n= 250884) andwho filled amethadone prescription between April 1, 2001, andMarch 31,
2015. Participants were followed from the date of first dispensedmethadone prescription until
censoring (date of death, or March 31, 2015). Data analysis was conducted fromMay 1 to August
31, 2018.
EXPOSURES Methadone treatment was divided into medicated (methadone was dispensed) and
nonmedicated (methadone was not dispensed) periods and analyzed as a time-varying exposure.
MAINOUTCOMEANDMEASURES Adjusted hazard ratios (aHRs) of acute hospitalizations for any
cause and cause-specific (substance use disorder [SUD], non–substance-related mental disorders
[NSMDs], and medical diagnoses [MEDs]) were estimated using multivariable Cox proportional
hazards regression.
RESULTS A total of 11 401 people (mean [SD] age, 34.9 [9.4] years; 8230 [72.2%]men) met
inclusion criteria and were followed up for a total of 69 279.3 person-years. During a median
follow-up time of 5.5 years (interquartile range, 2.8-9.1 years), there were 19 160 acute hospital
admissions. Dispensedmethadone was associated with a 50% lower rate of hospitalization for any
cause (aHR, 0.50; 95% CI, 0.46-0.53) during the first 2 years (2.0 years) following methadone
initiation, demonstrating significantly lower rates of admission for SUD (aHR, 0.32; 95% CI,
0.27-0.38), NSMD (aHR, 0.41; 95% CI, 0.34-0.50), andMED (aHR, 0.57; 95% CI, 0.52-0.62). As
duration of time increased (2.1 to5.0 years; 5.1 to10.0 years), methadone was associated with a
significant but smaller magnitude of effect: SUD (aHR, 0.43; 95% CI, 0.36-0.52; aHR, 0.47; 95% CI,
0.37-0.61), NSMD (aHR, 0.51; 95% CI, 0.41-0.64; aHR, 0.60; 95% CI, 0.47-0.78), and MED (aHR,
0.71; 95% CI, 0.65-0.77; aHR, 0.85; 95% CI, 0.76-0.95).
CONCLUSIONS ANDRELEVANCE In this study, methadone was associated with a lower rate of
hospitalization among a large cohort of Canadian individuals with histories of convictions and
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Abstract (continued)
prevalent concurrent health and social needs. Practices to improvemethadone adherence are
warranted.
JAMA Network Open. 2019;2(3):e190595. doi:10.1001/jamanetworkopen.2019.0595
Introduction
Rising rates of opioid misuse and dependence contribute directly to mortality1,2 and disability.3
Substance use disorders (SUDs) are overrepresented in correctional settings and among people with
criminal histories.4 More than half of individuals involved with the justice system report heroin or
other drug use prior to incarceration5 concurrent with endemic psychiatric disorders and infectious
diseases.6-8 Opioid and other SUDs are often accompanied by complex health needs9 and
overwhelm acute health care services.10 Opioids in particular are associated with hospitalizations11,12
and emergency department use13 for general as well as offender populations. Canadian surveillance
indicates that overdose-related hospitalizations rose 53% over the past decade,14 with comparable
increases internationally.15 In addition, medical issues (eg, soft-tissue infections, infectious diseases)
secondary to injection drug use and other risky behaviors place demands on acute care.16-18 Once
hospitalized, patients using opioids have longer lengths of stay19 and higher rates of readmission,20
with high related costs.21 Economic analyses concerning people who are opioid dependent reveal
frequent criminal involvement,22 poor health status,6 and a reliance on hospital services, resulting in
a societal cost in excess of $4 billion ($CDN) per year in Canada.23 Almost all incarcerated individuals
are eventually released to the community, but few inmates with opioid use disorder are released to
evidence-based interventions, which remain underused in prisons24,25 and communities.26,27
A body of research supports the use of methadone maintenance treatment (MMT) to reduce
harms associated with opioid use disorder.28 Engagement in MMT is associated with reduced
mortality29 and criminal activity,30 as well as lower health care costs.31,32 In a systematic review,33
MMTwas associated with more health benefits and less cost than no drug treatment and wasmore
cost-effective than other agonist treatment options. Although reduced costs may signify diversion
from acute care, few studies have examined the association between methadone adherence and
hospitalization, and, to our knowledge, none are specific to people with criminal convictions.
In a recent prospective cohort study comparing implanted naltrexone with methadone and
buprenorphine, methadone treatment participation was associated with significantly lower rates of
hospital admissions and emergency department use.34 The study found that receipt of methadone
with carry privileges was associated with significantly lower odds of hospital admission,35 although
this method of dispensing is relatively uncommon. Other studies have reported an association
betweenmethadone treatment engagement and lower rates of hospitalization based on relatively
small sample sizes36 and short follow-up periods.37
We investigated the association between dispensedmethadone and hospitalization in the
population with histories of criminal convictions in British Columbia, Canada, over a 14-year period.
We aimed to provide clinical and epidemiologic details of the population and address 2 primary
questions related tomethadone: Is the risk of hospital admission lower during periods of dispensed
methadone compared with nondispensed methadone periods? Is the risk of substance-related
hospital admission lower during periods of dispensedmethadone relative to other reasons for
admission (eg, psychiatric or medical)?
Methods
Participants andData Source
Data were obtained by linking population-level administrative records in British Columbia under the
Inter-Ministry Research Initiative. The study cohort consisted of all individuals with histories of
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provincial justice contacts (n = 250884) in British Columbia. Those who filled a methadone
prescription between April 1, 2001, andMarch 31, 2015, were eligible for inclusion. We used several
population-level databases: the Ministry of Health’s PharmaNet and Discharge Abstract databases
and the Ministry of Justice’s registry of convictions. Data were analyzed fromMay 1 to August 31,
2018. Databases and variables used in this study are listed in eMethods 1, eTable 1, and eTable 2 in the
Supplement. Additional details of the Inter-Ministry Research Initiative that are not essential to the
present study have been described elsewhere.38 The Inter-Ministry Research Initiative serves as a
resource for the development of policies and services that span health, justice, and social
welfare sectors.
Follow-up extended from the date of first dispensedmethadone prescription until censoring
(date of death or March 31, 2015). Methadone prescription transactions were collected by the
Ministry of Health. Corrections and sociodemographic variables (age, sex, ethnicity, and educational
level) were collected by the Ministry of Justice. Ethnicity of participants was ascribed by personnel
in theMinistry of Justice, and these categories were used by the study investigators. Hospitalization
data were obtained from the Ministry of Health’s Discharge Abstract Database, which includes
information related to each acute hospital separation. Covariate information concerningmedical and
laboratory service use was extracted from the Provincial Medical Services Plan database, which
details the date, diagnostic code, and cost associated with medical services to citizens in British
Columbia, including while serving sentences under provincial corrections. The study used exclusively
retrospective deidentified administrative records and consent was not possible. The study was
reviewed and approved without need for waiver of informed consent by the Simon Fraser University
Research Ethics Board. This study followed the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) reporting guideline.
Measures
Data on themain exposure (methadone) were extracted from the PharmaNet database, a
provincewide network linking all prescriptions issued by British Columbia pharmacies. This register
omits dispensing information during hospitalization or outside the province of British Columbia.
Authorized physicians who hold an exemption fromHealth Canada are permitted to prescribe
methadone in British Columbia.39 Methadone is dispensed to individuals whomeet criteria for opioid
dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition),
and/or Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision). People
receiving methadone are required to comply with daily witnessed ingestion under the supervision of
a pharmacist (ie, attend pharmacy daily to receive dispensed dose ofmethadone) unless authorized
to hold carry privileges.39
Methadone was treated as a time-varying exposure (ie, medication status was not constant
throughout follow-up), and each participant’s follow-upwas divided intomedicated (methadonewas
dispensed) and nonmedicated (methadonewas not dispensed) periods. Following themethod used
in previous research,30 a participant was considered exposed tomethadone based on pharmacy fill
transaction dates. If a participant filled their methadone prescription consistently (no gap in
pharmacy transaction dates), the duration of these consistent fills was treated as a single interval/
episode and considered as a medicated period (methadone was dispensed). If there were gaps in
pharmacy transaction dates, the interval was considered a nonmedicated period (methadone was
not dispensed). Participants were expected to alternate between medicated and nonmedicated
periods (further details and illustration are presented in eMethods 2 and eTables 3-6 in the
Supplement).
Themain outcomewas 1 or more acute hospital admissions for any cause during follow-up
(excluding interhospital transfers). Hospitalizations were classified bymost responsible diagnosis for
each patient’s stay in the hospital. The present study used International Statistical Classification of
Diseases and Health Problems, Tenth Revision, Canada (ICD-10-CA) to determine themost
responsible diagnosis, a modified version of ICD-10, developed by Canadian Institute of Health
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Information and used across Canada. Using ICD-10-CA codes, we subdivided hospital admissions for
any cause into 3 categories: SUDs (eg, opioids, alcohol), non–substance-related mental disorders
(NSMDs) (eg, schizophrenia, depression), and all other medical diagnoses (MEDs) (eg, HIV, cellulitis,
or pneumonia). The ICD-10-CA coding algorithms have been available in British Columbia since April
1, 2001. Diagnostic codes related to SUD, NSMD, and MED are reported in eTables 7-11 in the
Supplement.
Statistical Analysis
We used descriptive statistics (counts and proportions for nominal variables) andmean (SD) or
median and interquartile range (IQR) for continuous variables to characterize the sample. The
dependent variable (outcome) was any acute hospital admission. We examined hospitalizations for
any cause followed by cause-specific analyses (SUD, NSMD, or MED). Time at risk started when
participants filled their first methadone prescription during the observation period and ended when
censoring occurred (date of death orMarch 31, 2015). Time spent in the hospital was excluded from
time at risk (eMethods 2 in the Supplement). We chose time-to-event analysis because our outcome
of interest was not only the occurrence of an event (hospitalization) but also when it occurred.
Methadone was our primary independent variable and was analyzed as a time-varying covariate
(medicated and nonmedicated periods) in the regressionmodel. Bothmedicated and nonmedicated
time segments for methadone were calculated using pharmacy-dispensing/transaction dates
(eMethods 2 in the Supplement). Owing to the recurrent nature of the outcome variable, we used the
Anderson-Gill counting process method,40 an extension of the Cox proportional hazards regression
model,41 to estimate the hazard of hospital admission associated with dispensedmethadone. During
themodel-building process, we assessed the proportional hazards regression assumption for
methadone and other covariates using Schoenfeld residuals.42 We found a violation of the
assumption of proportionality of methadone in the univariate Cox proportional hazards regression
model and refitted the univariate Cox proportional hazards regression model with the interaction
terms betweenmethadone and follow-up time at 3 discrete time points (2.0, 5.0, and 10.0 years).
This model provided estimates of hazard ratios (HRs) for methadone in each temporal segment
(2.0 years [730 days], 2.1 to5.0 years [731-1826 days], 5.1 to10.0 years [1827-3652 days], and
>10.0 years [3653-5111 days]). Themultivariable Cox proportional hazards regressionmodel included
methadone and temporal interaction terms as well as controlling variables selected based on their
established associations with future hospital admissions13,19,32,37,43-45: age at enrollment, sex,
ethnicity, educational level, calendar year, offenses in the previous year, medical services plan cost in
the previous year, SUD-related services in the previous year, severe mental illness (ever), and
hospitalizations in the previous year (eTable 12 in the Supplement provides a description of study
variables).
As an effect size, we report the adjusted HR (aHR) and 95% CI. We also report the risk
difference, calculated using the formula I0 × (aHR − 1), where I0 is the unadjusted event rate in the
unexposed group. To account for dependencies between events within the same individual, we used
the robust variance estimator to estimate SEs for parameters.46,47We chose the conventional α level
(2-tailed P  .05) to interpret the significance of estimated parameters. People with missing
demographic information, including ethnicity and educational level, were included in our analyses
under the categories titled unknown ethnicity and unknown educational level.
We conducted several subgroup and sensitivity analyses to examine whether our primary
results were altered by differences in cohort selection and varying durations of exposure.
Associations were examined across 4 subgroups categorized based on different durations of
exposure (very short, short, long, and very long) (eTables 13-16 in the Supplement). In addition, we
examined participants who exclusively received methadone (no buprenorphine or
buprenorphine-naloxone) during the study (eTable 17 in the Supplement). There is evidence
demonstrating an association between injection drug use and skin or soft-tissue infections (eg,
cellulitis or abscess).48,49 To investigate this outcome in the present sample, we conducted
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additional cause-specific analyses for hospitalizations related to themost responsible diagnoses of
cellulitis or abscess (eTable 18 in the Supplement).
Results
The sample comprised 11 401 people (Figure) (mean [SD] age, 34.9 [9.4] years; 8230 [72.2%]men)
who, from April 1, 2001, to March 31, 2015, were followed up for a total of 69 279.3 person-years
(PYs). Baseline sociodemographic, criminologic, and hospitalization details for the eligible sample are
presented in Table 1. During amedian follow-up time of 5.5 years (IQR, 2.8-9.1 years), there were
19 160 acute hospital admissions—amean (SD) of nearly 2 admissions (1.7 [3.5]) per person or a rate
of 27.8 admissions per 100 PYs. A total of 5454 participants (47.8%) had at least 1 acute admission
during follow-up. Medical diagnoses accounted for the highest frequency of admissions to hospital
(13 273), followed by those related to SUD (1541) and NSMD (1004). The median (IQR) number of
medicated and nonmedicated treatment years (1.6 [0.4-3.9] and 2.5 [0.7-5.2] years, respectively)
represented a total medicated treatment time of 29 706.8 PYs and a nonmedicated treatment time
of 39 572.4 PYs. A total of 155 participants (1.4%) were dispensed methadone for the entire
observation period (no nonmedicated periods), and 971 participants received buprenorphine or
buprenorphine-naloxone in the follow-up period. Only a single participant received buprenorphine,
and all others received buprenorphine-naloxone.
For hospital admissions due to any cause (Table 2), dispensedmethadone was associated with
a 50% lower rate of hospitalization (aHR, 0.50; 95% CI, 0.46-0.53) during the first 2 years (2.0
years) followingmethadone initiation, equating to a risk difference of 20.7 fewer hospital admissions
per 100 PYs.Moreover, dispensedmethadonewas associatedwith a lower rate of admission for SUD
(aHR, 0.32; 95% CI, 0.27-0.38), NSMD (aHR, 0.41; 95% CI, 0.34-0.50), and MED (aHR, 0.57; 95%
CI, 0.52-0.62) during the first 2 years of treatment (Table 3). As duration of time following
methadone initiation increased (2.1 to5.0 years; 5.1 to10.0 years), smaller but statistically
significant associations between dispensedmethadonewere observed for admissions related to SUD
(2.1 to5.0 years: aHR, 0.43; 95% CI, 0.36-0.52; 5.1 to10.0 years: aHR, 0.47; 95% CI, 0.37-0.61),
NSMD (2.1 to5.0 years: aHR, 0.51; 95% CI, 0.41-0.64; 5.1 to10.0 years; aHR, 0.60; 95% CI,
0.47-0.78), andMED (2.1 to5.0 years: aHR, 0.71; 95% CI, 0.65-0.77; 5.1 to10.0 years: aHR, 0.85;
95% CI, 0.76-0.95).
Dispensedmethadone was not associated with significant reductions in hospitalization risk in
periods exceeding 10.0 years following methadone initiation with the exception of NSMD-related
hospitalizations (aHR, 0.51; 95% CI, 0.32-0.81). After exclusion of participants who died during
follow-up (n = 762), the association between dispensedmethadone and lower risk of hospitalization
for any cause remained significant across all time segments up to 10 years followingmethadone
initiation (2.0 years: aHR, 0.50; 95% CI, 0.46-0.54; 2.1 to5.0 years: aHR, 0.62; 95% CI,
0.57-0.68; and 5.1 to10.0 years: aHR, 0.74; 95% CI, 0.66-0.82) (Table 4).
Figure. Flowchart of PatientsWith Convictions in British Columbia (BC), 2001-2015,
WhoWere ReceivingMethadone
250 884 Individuals with Ministry of Justice contacts in BCa
11 401 Eligible for present study
12 799 Filled methadone prescription 
1398 Excluded
1377 No history of convictionsb
19 Early initiation (<18 y) of methadone
2 Missing age
a The cohort included participants (offenders) who
had convictions (found or pleaded guilty and
sentenced) as well as those (nonoffenders) who did
not have any convictions but were under supervision
of theMinistry of Justice due to remand or bail and
later found not guilty (nonoffenders).
b This time period included the study/exposure period
(April 1, 2001, to March 31, 2015) for methadone as
well as the time before enrollment (from the time
when justice databases became available in
January 1997).
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Table 1. Sociodemographic, Methadone, and Crime-Related Characteristics of 11 401 PatientsWith Convictions
in British Columbia, 2001-2015,WhoWere ReceivingMethadone
Variable No. (%)
Age at enrollment, ya
Mean (SD) 34.9 (9.4)
Median (IQR) [range] 33.6 (27.3-41.5) [18.0-74.9]
Age groups, y
18 to < 25 1812 (15.9)
25 to < 35 4431 (38.9)
35 to < 45 3296 (28.9)
45 to < 55 1562 (13.7)
≥55 300 (2.6)
Men 8230 (72.2)
Ethnicity
White 8196 (71.9)
Indigenous 1758 (15.4)
Other 993 (8.7)
Unknown 454 (4.0)
Educational level
<Grade 10 1483 (13.0)
Grade 10 or 11 3926 (34.4)
Grade 12 3765 (33.0)
Vocational or university 1303 (11.4)
Unknown 924 (8.1)
Follow-up period, yb
Mean (SD) 6.1 (4.0)
Median (IQR) [range] 5.5 (2.8-9.1) [<0.1-14.0]
Total follow-up time, PYs 69 279.3
Hospital length of stay during follow-up period, d
Mean (SD) 14.7 (42.0)
Median (IQR) [range] 0 (0-9) [0-928]
Total hospital stay, y 459.5
Time at risk, yc
Mean (SD) 6.0 (3.9)
Median (IQR) [range] 5.4 (2.8-9.0) [<0.1-14.0]
Total time at risk, y 68 819.8
Year of methadone initiation
2001-2005 3026 (26.5)
2006-2010 4313 (37.8)
2011-2015d 4062 (35.6)
Medicated period, y
Mean (SD) 2.6 (2.8)
Median (IQR) [range] 1.6 (0.4-3.9) [<0.1-13.8]
Total medicated time, PYs 29 706.8
No. of medicated periods or episodes
Mean (SD) 37.3 (49.9)
Median (IQR) [range] 19 (6-49) [1-501]
Nonmedicated period, y
Mean (SD) 3.5 (4.0)
Median (IQR) [range] 2.5 (0.7-5.2) [0.0-14.0]
Total nonmedicated time, PYs 39 572.4
No. of nonmedicated periods or episodese
Mean (SD) 36.9 (49.8)
Median (IQR) [range] 19 (5-48) [0-501]
(continued)
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Sensitivity and SubgroupAnalyses
The association between hospitalization and dispensedmethadone was further investigated in
subgroup and sensitivity analyses (eTables 13-18 in the Supplement). After repeating our analyses
using varying durations of exposure (2.0 years [very short]; 2.1 to5.0 years [short]; and 5.1 to
10.0 years [long]), the risk of acute hospitalization was lower during periods of dispensed
methadone in each instance (eTables 13-15 in the Supplement). When restricted to those with at least
10 years of follow-up (n = 2322), the association between dispensedmethadone and hospitalizations
for any causewas attenuated across very longmethadone treatment periods (>10.0 years) (eTable 16
in the Supplement). In time periods up to and including 10 years, methadone treatment was
associated with a significantly lower risk of hospitalization (2.0 years: aHR 0.49; 95% CI,
0.46-0.53; 2.1 to5.0 years: 0.64; 95% CI, 0.59-0.70; and 5.1 to10.0 years: 0.76; 95% CI, 0.69-
0.85) (eTable 17 in the Supplement) among participants with methadone monotherapy (n=10 430)
and no other forms of opioid agonist treatment (buprenorphine or buprenorphine-naloxone) and did
not differ from our main results. In sensitivity analyses, we separately examined hospitalizations
related to specific MEDs (abscess and cellulitis) (eTable 18 in the Supplement), which supported the
Table 1. Sociodemographic, Methadone, and Crime-Related Characteristics of 11 401 PatientsWith Convictions
in British Columbia, 2001-2015,WhoWere ReceivingMethadone (continued)
Variable No. (%)
No. of methadone transactions in the year after enrollment
(n = 10 376), mean (SD)f
166.9 (120.6)
Received buprenorphine or buprenorphine-naloxone in follow-up
period
971 (8.5)g
Pharmacy transactions in the year after enrollment (n = 930), mean
(SD)h
No. of buprenorphine or buprenorphine-naloxone transactions 7.8 (29.9)
No. of methadone transactions 152.0 (111.7)
Severe mental illness, No. (%)
No schizophrenia or bipolar disorder 7374 (64.7)
Schizophrenia 1772 (15.5)
Bipolar disorder 2255 (19.8)
No. of offenses in the year prior to enrollment, mean (SD) 1.0 (2.0)
Any offense in the year prior to enrollment, offenses, No. (%)
None 7202 (63.2)
1-2 2664 (23.4)
>2 1535 (13.5)
No. of jail sentences in the year prior to enrollment, mean (SD) 0.6 (1.7)
Participants with ≥1 jail sentence in the year prior to enrollment, No.
(%)
2175 (19.1)
Jail sentence during follow-up period
Mean (SD), No. 2.8 (6.2)
Median (IQR) [range], No. 0 (0-3) [0-86]
Total jail sentences, No. 31 498
Rate per PY 0.45
≥1 Jail sentence, No. (%) 4143 (36.3)
MSP cost in the year prior to enrollment, No. (%), $i
First quartile (≤295)j 2851 (25.0)
Second quartile (296-751) 2850 (25.0)
Third quartile (752-1743) 2850 (25.0)
Fourth quartile (≥1744) 2850 (25.0)
MSP services (SUD related) in the year prior to enrollment, No. (%)
Low (≤1)k 5841 (51.2)
Medium (2-6) 2957 (25.9)
High (≥7) 2603 (22.8)
Abbreviations: IQR, interquartile range; MSP, medical
services plan; PYs, person-years; SUD, substance use
disorder.
a Age at enrollment was based on date of initiation of
methadone treatment (between April 1, 2001, to
March 31, 2015).
b The follow-up period was estimated from the time
difference between time 0 (initiation of methadone)
and study end (death or March 31, 2015).
c Length of stay during the follow-up period was
excluded from the analysis time. Time at risk was
calculated subtracting the hospital days from the follow-
up period.
d Only 3months (January to March) of data were
included in 2015.
e A total of 155 participants (1.4%) did not have any
nonmedicated treatment periods and received
methadone during the entire observation period.
f Restricted to participants (n = 10 376) who had at
least 1 year of follow-up.
g Only a single participant received buprenorphine; all
others received buprenorphine-naloxone.
h Restricted to participants (n = 930) who received
buprenorphine or buprenorphine-naloxone and had
at least 1 year of follow-up.
i All costs in Canadian dollars.
j The 25th, 50th, and 75th percentiles were used to
categorize MSP costs into 4 separate groups.
k The 50th and 75th percentiles were used to
categorize the groups as low, medium, and high.
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association between dispensedmethadone and lower risk of hospital admission across shorter
follow-up periods (2.0 years; 2.1 to5.0 years) but diminished in periods exceeding 5 years.
Discussion
Dispensedmethadone was associated with a significantly lower risk of hospitalization for any cause
among individuals with opioid dependence and histories of criminal convictions. To our knowledge,
this is the first study to investigate the association between methadone adherence and hospital
admissions in a large sample (>10000) over periods exceeding 10 years.
We found that dispensedmethadone was associated with a significantly lower risk of
hospitalization for SUD, NSMD, andMED, and that among these conditions, the greatest magnitude
of association was with SUD. The health status of people in our sample is consistent with prior
epidemiologic findings involving individuals with criminal histories, confirming significant health
inequities50 andmultiple comorbidities necessitating acute intervention.51,52 Our results
demonstrate substantial risk for hospitalizations related to psychiatric and othermedical issues when
individuals were not receivingmethadone. This outcome is expected given the evidence that health
service use is highest among offenders with co-occurring substance use andmental illness in
comparison with either disorder alone.53,54 The opportunity to reduce the risk of acute hospital
admissions via methadone should be considered in combination with recovery-oriented
frameworks55 and long-term care needs56 targeting individuals with co-occurring disorders.57 In
addition, we observed a statistically significant association between any acute admission and
methadone during the first 2 years following treatment initiation and extending beyond a decade for
psychiatric-related hospitalizations. Our findings support calls for integrated58,59 and inclusive60
health care (eg, opioid use, psychiatric disorders), pharmacotherapy, and non–health-related services
(eg, housing, psychosocial support) in a patient-centered and low barrier approach.61
Nearly all incarcerated individuals return to the community and face distinct health and social
risks during this transition.62 Continuity of care is often compromised, and discrimination contributes
to suboptimal substance use treatment engagement,63 promoting a reliance on acute hospital
Table 2. Extended Cox Proportional Hazards Regression Analysis Estimating the Hazards AssociatedWithMethadone for Any-Cause Acute Hospitalizations
Among 11 401 PatientsWith Convictions in British Columbia, 2001-2015,WhoWere ReceivingMethadone
Time Segment, ya
Period
Receiving
Methadone
Total
Admissions, No. Total PYs
Incidence
per 100 PYs
HR (95% CI)
Risk Difference
per 100 PYs (95% CI)eUnadjustedb,c Adjustedd
≤2.0 No 4129 9984.5 41.4 1 [Reference] 1 [Reference]
Yes 2416 10 612.5 22.8 0.52 (0.48 to 0.56) 0.50 (0.46 to 0.53) −20.7 (−22.3 to −19.4)
2.1 to ≤5.0 No 4485 14 043.6 31.9 1 [Reference] 1 [Reference]
Yes 2057 9206.6 22.3 0.70 (0.65 to 0.76) 0.63 (0.59 to 0.69) −11.8 (−13.1 to −9.9)
5.1 to ≤10.0 No 3228 12 020.6 26.9 1 [Reference] 1 [Reference]
Yes 1746 7889.5 22.1 0.82 (0.75 to 0.91) 0.75 (0.68 to 0.83) −6.7 (−8.6 to −4.6)
>10.0 No 646 3101.8 20.8 1 [Reference] 1 [Reference]
Yes 453 1960.7 23.1 1.11 (0.92 to 1.34) 1.00 (0.83 to 1.21) 0.0 (−3.5 to 4.4)
Overall No 12 488 39 150.5 31.9
NA NA NAYes 6672 29 669.3 22.5
Total 19 160 68 819.8 27.8
Abbreviations: HR, hazard ratio; NA, not applicable; PYs, person-years.
a The ranges of days for the 4 time segments are as follows: 730 days or less (2.0
years), 731 to 1826 days (2.1 to5.0 years), 1827 to 3652 days (5.1 to10.0 years), and
3653 to 5111 days (>10.0 years).
b This Cox proportional hazards regressionmodel includes treatment and the interaction
terms with time segments at 2.0, 5.0, and 10.0 years.
c The 95% CIs and both unadjusted and adjusted HRs were estimated using robust SEs.
d Themultivariable Cox proportional hazards regressionmodel was controlled for age at
enrollment (18 to <25, 25 to <35, 35 to <45, 45 to <55, and55 years), sex (men and
women), ethnicity (white, indigenous, other, and unknown), educational level (less
than grade 10, grade 10 or 11, grade 12, vocational or university, and unknown), calendar
year (2001-2005, 2006-2010, and 2011-2015), offenses in the previous year (none,
1-2, and3 offenses), medical services plan cost in the previous year (quartile
variable), substance use disorder–related services in the previous year (0-1, 2-6, and7
services), severe mental illness (no schizophrenia or bipolar disorder, schizophrenia
and bipolar disorder), and hospitalizations in the previous year (no vs yes).
e Risk difference was calculated using the formula: I0 × (adjusted HR − 1), where I0
indicates unadjusted event rate in the unexposed group (nonmedicated).
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Table 3. Extended Cox Proportional Hazards Regression Analysis Estimating the Hazards AssociatedWithMethadone for SUD-, NSMD-, andMED-Related
Hospitalizations Among 11 401 PatientsWith Convictions in British Columbia, 2001-2015,WhoWere ReceivingMethadone a,b,c
Time Segment, yd
Period Receiving
Methadone
Total
Admissions Total PYs
Incidence
per 100 PYs
HR (95% CI)
Risk Difference
per 100 PYs (95% CI)hUnadjustede,f Adjustedg
SUD
≤2.0 No 850 9984.5 8.5 1 [Reference] 1 [Reference]
Yes 309 10 612.5 2.9 0.33 (0.28 to 0.38) 0.32 (0.27 to 0.38) −5.8 (−6.2 to −5.3)
2.1 to ≤5.0 No 821 14 043.6 5.8 1 [Reference] 1 [Reference]
Yes 268 9206.6 2.9 0.50 (0.41 to 0.60) 0.43 (0.36 to 0.52) −3.3 (−3.7 to −2.8)
5.1 to ≤10.0 No 586 12 020.6 4.9 1 [Reference] 1 [Reference]
Yes 214 7889.5 2.7 0.56 (0.44 to 0.71) 0.47 (0.37 to 0.61) −2.6 (−3.1 to −1.9)
>10.0 No 100 3101.8 3.2 1 [Reference] 1 [Reference]
Yes 70 1960.7 2.9 0.90 (0.58 to 1.39) 0.76 (0.49 to 1.16) −0.8 (−1.6 to 0.5)
Overall No 2357 39 150.5 6.0
NA NA NAYes 848 29 669.3 2.9
Total 3205i 68 819.8 4.7
NSMD
≤2.0 No 549 9984.5 5.5 1 [Reference] 1 [Reference]
Yes 270 10 612.5 2.5 0.44 (0.36 to 0.53) 0.41 (0.34 to 0.50) −3.2 (−3.6 to −2.7)
2.1 to ≤5.0 No 536 14 043.6 3.8 1 [Reference] 1 [Reference]
Yes 222 9206.6 2.4 0.63 (0.51 to 0.79) 0.51 (0.41 to 0.64) −1.9 (−2.3 to −1.4)
5.1 to ≤10.0 No 369 12 020.6 3.1 1 [Reference] 1 [Reference]
Yes 186 7889.5 2.4 0.77 (0.59 to 1.00) 0.60 (0.47 to 0.78) −1.2 (−1.6 to −0.7)
>10.0 No 70 3101.8 2.3 1 [Reference] 1 [Reference]
Yes 30 1960.7 1.5 0.67 (0.42 to 1.07) 0.51 (0.32 to 0.81) −1.1 (−1.5 to −0.4)
Overall No 1524 39 150.5 3.9
NA NA NAYes 708 29 669.3 2.4
Total 2232j 68 819.8 3.2
MED
≤2.0 No 2730 9984.5 27.3 1 [Reference] 1 [Reference]
Yes 1837 10 612.5 17.3 0.59 (0.55 to 0.65) 0.57 (0.52 to 0.62) −11.8 (−13.1 to −10.4)
2.1 to ≤5.0 No 3128 14 043.6 22.3 1 [Reference] 1 [Reference]
Yes 1567 9206.6 17.0 0.76 (0.70 to 0.83) 0.71 (0.65 to 0.77) −6.5 (−7.8 to −5.1)
5.1 to ≤10.0 No 2273 12 020.6 18.9 1 [Reference] 1 [Reference]
Yes 1346 7889.5 17.1 0.90 (0.81 to 1.01) 0.85 (0.76 to 0.95) −2.8 (−4.5 to −0.9)
>10.0 No 476 3101.8 15.3 1 [Reference] 1 [Reference]
Yes 366 1 960.7 18.7 1.22 (0.98 to 1.51) 1.15 (0.93 to 1.43) 2.3 (−1.1 to 6.6)
Overall No 8607 39 150.5 22.0
NA NA NAYes 5116 29 669.3 17.2
Total 13 273 68 819.8 19.9
Abbreviations: HR, hazard ratio; MED, medical diagnoses; NA, not applicable; NSMD,
non–substance-relatedmental disorder; PYs, person-years; SUD, substance use disorder.
a Hospitalizations associated with SUDwere determined usingmost responsible
(primary) diagnostic codes (F10-F19) for in-hospital stay.
b Hospitalizations associated with NSMDwere determined usingmost responsible
(primary) diagnostic codes (F00-F09; F20-F99) for in-hospital stay.
c Nonpsychiatric hospitalizations were determined usingmost responsible (primary)
diagnostic codes for in-hospital stay and included all the residual diagnostic codes
excluding codes for NSMD (F00-F09, F20-F99) and SUD (F10-F19).
d The ranges of days for the 4 time segments are as follows: 730 days or less (2.0
years), 731 to 1826 days (2.1 to5.0 years), 1827 to 3652 days (5.1 to10.0 years), and
3653 to 5111 days (>10.0 years).
e This Cox proportional hazards regressionmodel includes treatment and the interaction
terms with time segments at 2.0, 5.0, and 10.0 years.
f The 95% CIs and both unadjusted and adjusted HRs were estimated using robust SEs.
g Themultivariable Cox proportional hazards regressionmodel was controlled for age at
enrollment (18 to <25, 25 to <35, 35 to <45, 45 to <55, and55 years); sex (men and
women); ethnicity (white, indigenous, other, and unknown), educational level (less
than grade 10, grade 10 or 11, grade 12, vocational or university, and unknown), calendar
year (2001 to 2005, 2006 to 2010 and 2011 to 2015), offenses in the previous year
(none, 1-2, and3 offenses), medical services plan cost in the previous year (quartile
variable), SUD-related services in the previous year (0-1, 2-6, and7 services), severe
mental illness (no schizophrenia or bipolar disorder, schizophrenia bipolar disorder),
and hospitalizations in the previous year (no vs yes).
h Risk difference was calculated using the formula: I0 × (adjusted HR − 1), where I0 is the
unadjusted event rate in the unexposed group (nonmedicated).
i Represents 16.7% of all hospital admissions (n = 19 160).
j Represents 11.6% of all hospital admissions (n = 19 160).
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services.64 This vulnerable period has signaled calls for partnerships between health and correctional
institutions to minimize exposure to unnecessary risks for both individual offenders and the
communities involved.65 Our results indicate that manymedical-related hospital admissions were
indirect consequences of opioid use (eg, cellulitis, HIV) and are preventable. Reviewers have
identified a substantial gap between policy66 and evidence-based approaches25,67 for people who
have been involved with the justice system.68 In attempts to bridge this gap, studies have evaluated
the importance of early engagement in primary care69 and team-based behavioral healthmodels in
the postrelease period,70 demonstrating significant reductions in emergency department use and
readmission rates, respectively. In light of the known harms of drug criminalization and the current
opioid crisis, it has been argued that there is amoral imperative to improve the standard of substance
use disorder care available to people under correctional supervision.71
Strengths and Limitations
Our study has several strengths, including its large population-based sample with nearly 2 decades
of comprehensive hospitalization and pharmacologic data. We also have limitations to consider. The
use of a Canadian populationwith correctional histories and health services that are publicly funded
may limit the generalizability of our results to other settings and jurisdictions. Our reliance on
administrative data is subject to bias related tomissing or incomplete records and errors associated
with prescriber judgment (eg, not initiating MMT despite being indicated). Our outcome was
restricted to admissions recorded in the provincial hospital database, and therefore it failed to
account for hospital admissions outside of British Columbia. Receipt of methadone treatment is
often accompanied by psychosocial supports, such as counseling, psychological treatments (eg,
motivational interviewing, cognitive behavioral therapy, or relapse prevention), Alcoholics
Anonymous, and Narcotics Anonymous, with varying degrees of access and participation among
individuals. Involvement with ancillary supports was not accounted for in our analyses andmay have
altered hospitalization risk independent of MMT.
Table 4. Subgroup Analysis Estimating the Hazards AssociatedWithMethadone for Any-Cause Acute Hospitalizations Among 10639 Surviving Patients
With Convictions in British Columbia, 2001-2015,WhoWere ReceivingMethadonea
Time Segment, yb
Period Receiving
Methadone
Total
Admissions, No. Total PYs
Incidence
per 100 PYs
HR (95% CI)
Risk Difference
per 100 PYs (95% CI)fUnadjustedc,d Adjustede
≤2.0 No 3557 9423.1 37.7 1 [Reference] 1 [Reference]
Yes 2061 9973.7 20.7 0.52 (0.48 to 0.56) 0.50 (0.46 to 0.54) −18.9 (−20.4 to −17.4)
2.1 to ≤5.0 No 3842 13 427.6 28.6 1 [Reference] 1 [Reference]
Yes 1713 8699.5 19.7 0.69 (0.63 to 0.75) 0.62 (0.57 to 0.68) −10.9 (−12.3 to −9.2)
5.1 to ≤10.0 No 2804 11 623.5 24.1 1 [Reference] 1 [Reference]
Yes 1486 7581.3 19.6 0.81 (0.73 to 0.90) 0.74 (0.66 to 0.82) −6.3 (−8.2 to −4.3)
>10.0 No 573 3063.1 18.7 1 [Reference] 1 [Reference]
Yes 402 1934.3 20.8 1.11 (0.92 to 1.36) 0.99 (0.82 to 1.21) −0.2 (−3.4 to 3.9)
Overall No 10 766 37 537.3 28.7
NA NA NAYes 5662 28 188.7 20.1
Total 16 438 65 726.0 25.0
Abbreviations: HR, hazard ratio; NA, not applicable; PYs, person-years.
a Analysis was restricted to participants who did not die during the study period (762
participants [6.7%] died during the study period).
b The ranges of days for the four time segments are as follows: 730 days or less (2.0
years), 731 to 1826 days (2.1 to5.0 years), 1827 to 3652 days (5.1 to10.0 years), and
3653 to 5111 days (>10.0 years).
c This Cox proportional hazards regressionmodel includes treatment and the interaction
terms with time segments at 2.0, 5.0, and 10.0 years.
d The 95% CIs and both unadjusted and adjusted HRs were estimated using robust SEs.
e Themultivariable Cox proportional hazards regressionmodel was controlled for age at
enrollment (18 to <25, 25 to <35, 35 to <45, 45 to <55, and55 years), sex (men and
women), ethnicity (white, indigenous, other, and unknown), educational level (less
than grade 10, grade 10 or 11, grade 12, vocational or university, and unknown), calendar
year (2001-2005, 2006-2010, and 2011-2015), offenses in the previous year (none,
1-2, and3 offenses), medical services plan cost in the previous year (quartile
variable), substance use disorder–related services in the previous year (0-1, 2-6, and7
services), severe mental illness (no schizophrenia or bipolar disorder, schizophrenia
and bipolar disorder), and hospitalizations in the previous year (no vs yes).
f Risk difference was calculated using the formula: I0 × (adjusted HR − 1), where I0
indicates unadjusted event rate in the unexposed group (nonmedicated).
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Methadoneprescribing in British Columbia almost universally involveswitnessedmethadone inges-
tion, and therefore our use of pharmacydispensing records provides a basis for inferringmethadone
adherence; however,we are unable to account for the potential diversion ofmethadone following ad-
ministration. Disruptions to treatment, such as relocation,were not assessed andmayhave influenced
the integrity of our results.Methadonedosewas not accounted for in our analysis, and although adose-
response relationship has been establishedbetweenmethadone andother treatment outcomes (eg,
retention), there is no clear evidence that dose is associatedwith hospital admission.35
Conclusions
Our study shows an association of opioid use with high rates of hospital admissions and
demonstrates an association betweenmethadone adherence and the likelihood of admission. Given
the complex physical andmental health needs of most opioid-dependent people, policies should
support engagement of those who are marginalized and at high risk for both hospitalization and
justice system involvement to improvemethadone adherence and overall recovery.
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